Search results
Added:
6 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
Author(s):
Renzo Laborante
,
Attilio Restivo
,
Daniela Mele
,
et al
Added:
9 months ago
ARNI for Optimising HFrEF Management
Author(s):
Massimo Iacoviello
,
Filippo M Sarullo
,
Claudio Bilato
,
et al
Added:
7 months ago
Expert Opinion
New Frontiers in Cardioprotection
Author(s):
Giulia Tamburrini
,
Celia de Cobos García
,
Teresa López Fernández
Added:
5 months ago
Review Article
Author(s):
Jelena Celutkiene
,
Alexandre Mebazaa
,
Jan Biegus
,
et al
Added:
1 year ago
Aldosterone and Potassium in Heart Failure
Author(s):
Laibah Arshad Khan
,
Adeena Jamil
,
Stephen J Greene
,
et al
Added:
1 year ago
Review Article
SGLT-2 Inhibitors and Heart Failure
Author(s):
C Noah Nilsson
,
Mads Kristian Ersbøll
,
Finn Gustafsson
Added:
1 year ago
Review Article
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s):
Rishi Sethi
,
Pravesh Vishwakarma
,
Akshyaya Pradhan
Added:
1 year ago
Review Article
Heart Failure Treatment and Cardiac Amyloidosis
Author(s):
Giorgia Panichella
,
Alberto Aimo
,
Vincenzo Castiglione
,
et al
Added:
7 months ago
Review Article
‘Residual Congestion’ in HF
Author(s):
Aleksandra Gasecka
,
Aleksander Siniarski
Added:
11 months ago
Review Article
